Results of ARMYDA-ACS trial show good outcome of 80 mg atorvastatin pretreatment in patients with acute coronary syndromes undergoing early percutaneous coronary intervention.;Badanie ARMYDA-ACS wskazuje na korzystny wpływ przedproceduralnego podania 80 mg atorwastatyny u chorych z ostrymi zespołami wieńcowymi leczonymi pietwotna angioplastyka.

Kardiologia polska

Volumn 65, Issue 7, 2007, Pages

  Michałek, Aleksandra ^a  

^a Miedzyleski Szpital Specjalistyczny w Warszawa   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ACUTE CORONARY SYNDROME; HUMAN; NOTE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; HEPTANOIC ACIDS; HUMANS; PYRROLES; TREATMENT OUTCOME;

EID: 38449123377     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (0)